Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma

NCT01465464 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

888

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Orantinib (TSU-68)
DRUG: Placebo

Sponsor

Taiho Pharmaceutical Co., Ltd.